Injection of nerve growth factor into human masseter muscle evokes long-lasting mechanical allodynia and hyperalgesia.
about
Myofascial Trigger Points Then and Now: A Historical and Scientific Perspective.Repeated muscle injury as a presumptive trigger for chronic masticatory muscle painSingle cycle structure-based humanization of an anti-nerve growth factor therapeutic antibodyTaking pain out of NGF: a "painless" NGF mutant, linked to hereditary sensory autonomic neuropathy type V, with full neurotrophic activityReview of overlap between thermoregulation and pain modulation in fibromyalgia.TRPV1 and TRPV4 play pivotal roles in delayed onset muscle soreness.Mechanisms of nerve growth factor signaling in bone nociceptors and in an animal model of inflammatory bone pain.Screening the role of pronociceptive molecules in a rodent model of endometriosis pain.Long lasting pain hypersensitivity following ligation of the tendon of the masseter muscle in rats: a model of myogenic orofacial painTowards a mechanism-based approach to pain management in osteoarthritisHeat-rekindling in UVB-irradiated skin above NGF-sensitized muscle: experimental models of prolonged mechanical hypersensitivity.Modulation of sensory neuron mechanotransduction by PKC- and nerve growth factor-dependent pathways.Effect of systemic monosodium glutamate (MSG) on headache and pericranial muscle sensitivity.Anatomical and physiological factors contributing to chronic muscle painSensitization of group III and IV muscle afferents in the mouse after ischemia and reperfusion injury.Antagonism of nerve growth factor-TrkA signaling and the relief of painTemporal mismatch between pain behaviour, skin Nerve Growth factor and intra-epidermal nerve fibre density in trigeminal neuropathic pain.The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain.Persistent Nociception Triggered by Nerve Growth Factor (NGF) Is Mediated by TRPV1 and Oxidative Mechanisms.A Mechanism-Based Approach to the Management of Osteoarthritis PainFundamentals of muscle pain, referred pain, and deep tissue hyperalgesia.Headache and mechanical sensitization of human pericranial muscles after repeated intake of monosodium glutamate (MSG).Effect of anti-NGF antibodies in a rat tibia fracture model of complex regional pain syndrome type I.Nerve growth factor alters microtubule targeting agent-induced neurotransmitter release but not MTA-induced neurite retraction in sensory neurons.Emerging drugs for osteoarthritis.Relationships between craniofacial pain and bruxism.Contribution of nerve growth factor to augmented TRPV1 responses of muscle sensory neurons by femoral artery occlusionAn overview of animal models of pain: disease models and outcome measures.Expression profile of nerve growth factor after muscle incision in the rat.The discovery and development of analgesics: new mechanisms, new modalities.Growth factors and neuropathic pain.Persistent orofacial muscle pain.Optimizing the early phase development of new analgesics by human pain biomarkers.Pro-neurotrophins, sortilin, and nociception.Prevention and reversal of latent sensitization of dorsal horn neurons by glial blockers in a model of low back pain in male rats.Effect of transdermal opioids in experimentally induced superficial, deep and hyperalgesic pain.Neurobiology of fibromyalgia and chronic widespread pain.Tanezumab in the treatment of chronic musculoskeletal conditions.Glial cell line-derived neurotrophic factor sensitized the mechanical response of muscular thin-fibre afferents in rats.Intradermal Injection with Nerve Growth Factor: A Reproducible Model to Induce Experimental Allodynia and Hyperalgesia.
P2860
Q27027808-5C93A4E2-724C-468D-9018-D5022768CA26Q28392760-FB9B538F-747B-4558-A6FF-749B0735CD10Q28731515-BDDF32BD-5CDB-430B-B507-D94EBB4C60E1Q28742340-02C0ED8D-1527-4D12-BFD9-3F8D2EFB2B69Q30410140-B97F4CE5-ED0D-4BC4-89A2-09BD91DECCB1Q31120400-29B7AABB-0B10-4E0B-A823-071078A30D9DQ33610520-750F3D93-FBF4-4D25-8686-4D0EAB318255Q33989677-1B9DE064-D361-4566-8B65-41DF841C4637Q34036354-A529783D-B840-4FDF-ACF7-C6313377D3E2Q34120813-044A031F-AB4C-423E-8400-D30633AC1D07Q34400389-754FFB93-59B7-42FE-BC8F-0338DC7F1F17Q34574943-A85FB87E-F5AB-4B00-9071-14EF73287FC1Q34607637-727FEF42-58F2-4B07-97CB-375D1FED82F1Q34958375-9EE2C5A3-CCB6-4227-B0AD-4FA324C70033Q34995893-E5B28529-AE42-4C72-BE61-2337FF79B0BFQ35064559-D15FD892-7539-49DD-881A-8F00B0FC8B64Q35079184-077171C8-FD54-433E-8ADD-67602310D275Q35669849-F1C92F47-8DE5-46DA-8FFE-F3087875889CQ35675208-0D752B48-DF4E-44F6-A8CA-5475C4789855Q36217637-5B508D01-30C6-4C2F-8E45-ADB3D4428821Q36602321-7C714B5B-56DB-42A1-A9EF-E8B19A68EEB0Q36712420-A055402D-9A62-4189-875B-A0A40F6F6D87Q36881864-3C823827-02E5-4F8A-A952-BE707445D2D0Q36884527-BC341B35-B347-4992-A8FA-8C8E6E563E1CQ36931658-73EB3686-6AD9-4A67-96B5-063BB1157DAFQ37192608-DA377F06-D1DE-4302-B140-8D43A9B08200Q37200185-7756BAA4-3CA1-4DF9-B2A6-24C1BAA30DC4Q37282107-3D3DA59C-B770-415A-96FA-CFAF9C2E7FB5Q37305721-1A773A0C-3B31-44A1-8405-8905D06F5B0AQ37805995-7256451E-FCC7-4CC1-9A6F-BA2CD83250A3Q37843774-14A3DDA9-DC42-46BA-BA45-E456F53345D9Q37850476-47A50176-DD9D-4AB0-BD48-EC4E88424FD6Q37947690-BACF4AEE-0F27-40BE-A1A1-5CDB5B585A52Q38185068-D6AB2C40-C2D3-4EC1-9CDB-FC85A016EDC2Q38725379-884E10DA-DFA3-4860-B564-4942A549952DQ38739959-A3EDEE0B-2841-4CDC-8C27-D42BACF1AC89Q38862596-528CDF66-262C-469C-9499-21F5F6B0CCB6Q39034462-468AACBD-3079-475E-9BE6-EADFCD0A9D8FQ39068508-DBDF4BAF-DA4F-4DD3-AE41-F11F91F8558AQ39084734-D009469C-53BE-4B67-A2A5-1BD9DF4C05EC
P2860
Injection of nerve growth factor into human masseter muscle evokes long-lasting mechanical allodynia and hyperalgesia.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Injection of nerve growth fact ...... al allodynia and hyperalgesia.
@en
type
label
Injection of nerve growth fact ...... al allodynia and hyperalgesia.
@en
prefLabel
Injection of nerve growth fact ...... al allodynia and hyperalgesia.
@en
P2093
P1433
P1476
Injection of nerve growth fact ...... al allodynia and hyperalgesia.
@en
P2093
Brian E Cairns
Kelun Wang
Peter Svensson
P304
P356
10.1016/S0304-3959(03)00012-5
P407
P577
2003-07-01T00:00:00Z